{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:14Z","timestamp":1786997894132,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005075","name":"Universitair Medisch Centrum Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202009110139"],"award-info":[{"award-number":["202009110139"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126563","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T01:25:51Z","timestamp":1733102751000},"page":"126563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Assessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system"],"prefix":"10.1016","volume":"44","author":[{"given":"Shuran","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Beukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"De Vries-Idema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Huckriede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2024.126563_bb0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.pcl.2024.01.018","article-title":"Vaccine Development","volume":"71","author":"Hammershaimb","year":"2024","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126563_bb0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/erv.09.148","article-title":"Animal models for the preclinical evaluation of candidate influenza vaccines","volume":"9","author":"Bodewes","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126563_bb0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4939-9550-9_12","article-title":"Vaccine development: from preclinical studies to phase 1\/2 clinical trials","volume":"2013","author":"Artaud","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126563_bb0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ilar\/ilv009","article-title":"Large animal models for vaccine development and testing","volume":"56","author":"Gerdts","year":"2015","journal-title":"ILAR J"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126563_bb0025","doi-asserted-by":"crossref","first-page":"Fso63","DOI":"10.4155\/fso.15.63","article-title":"Animal models are essential to biological research: issues and perspectives","volume":"1","author":"Barr\u00e9-Sinoussi","year":"2015","journal-title":"Future Sci OA"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126563_bb0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029132","article-title":"What is the predictive value of animal models for vaccine efficacy in humans? Reevaluating the potential of mouse models for the human immune system","volume":"10","author":"Jameson","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.vaccine.2024.126563_bb0035","first-page":"9","article-title":"Current progress in the development of a prophylactic vaccine for HIV-1","volume":"5","author":"Gamble","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.vaccine.2024.126563_bb0040","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6113.S8-001","article-title":"Animal models and the development of an HIV vaccine","author":"Greek","year":"2012","journal-title":"J AIDS Clinical Res"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126563_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/vaccines5030021","article-title":"Distinctive responses in an in vitro human dendritic cell-based system upon stimulation with different influenza vaccine formulations","volume":"5","author":"Tapia-Calle","year":"2017","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126563_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/vaccines7040181","article-title":"A PBMC-based system to assess human T cell responses to influenza vaccine candidates in vitro","volume":"7","author":"Tapia-Calle","year":"2019","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126563_bb0055","first-page":"431","article-title":"In vitro assessment of tick-borne encephalitis vaccine: suitable human cell platforms and potential biomarkers","volume":"38","author":"Signorazzi","year":"2021","journal-title":"ALTEX"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126563_bb0060","first-page":"431","article-title":"Assessment of tick-borne encephalitis vaccine: suitable human cell platforms and potential biomarkers","volume":"38","author":"Signorazzi","year":"2021","journal-title":"Altex-Altern Anim Ex"},{"key":"10.1016\/j.vaccine.2024.126563_bb0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.coi.2021.06.003","article-title":"New insights into B cells as antigen presenting cells","volume":"70","author":"Ghosh","year":"2021","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126563_bb0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/cei\/uxac090","article-title":"Cytokine production by human B cells: role in health and autoimmune disease","volume":"210","author":"de Gruijter","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2024.126563_bb0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2019.00201","article-title":"The role of B cells and antibodies in multiple sclerosis, Neuromyelitis Optica, and related disorders","volume":"10","author":"H\u00e4usser-Kinzel","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126563_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"5601","key":"10.1016\/j.vaccine.2024.126563_bb0085","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126563_bb0090","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/eji.200535744","article-title":"Toll-like receptor stimulation as a third signal required for activation of human naive B cells","volume":"36","author":"Ruprecht","year":"2006","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126563_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011776","article-title":"Examining B-cell dynamics and responsiveness in different inflammatory milieus using an agent-based model","volume":"20","author":"Shin","year":"2024","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126563_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051183","article-title":"Minimalistic in vitro culture to drive human naive B cell differentiation into antibody-secreting cells","volume":"10","author":"Unger","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126563_bb0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/08916934.2012.749244","article-title":"Regulation of Aicda expression and AID activity","volume":"46","author":"Zan","year":"2013","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126563_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri1337","article-title":"TLR ligands from the natural world","volume":"4","author":"Honey","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126563_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000138","article-title":"Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by toll-like receptor signalling","volume":"4","author":"Geeraedts","year":"2008","journal-title":"PLoS Pathog"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126563_bb0120","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.4049\/jimmunol.1600046","article-title":"Whole-Virion influenza vaccine recalls an early burst of high-affinity memory B cell response through TLR signaling","volume":"196","author":"Onodera","year":"2016","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126563_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020423","article-title":"Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126563_bb0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"6813","key":"10.1016\/j.vaccine.2024.126563_bb0135","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126563_bb0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126563_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1750-2659.2008.00038.x","article-title":"Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs","volume":"2","author":"Geeraedts","year":"2008","journal-title":"Influenza Other Respi Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126563_bb0150","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126563_bb0155","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.4049\/jimmunol.174.7.4043","article-title":"Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN","volume":"174","author":"Bekeredjian-Ding","year":"2005","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126563_bb0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/eji.201646574","article-title":"B-cell activation with CD40L or CpG measures the function of B-cell subsets and identifies specific defects in immunodeficient patients","volume":"47","author":"Marasco","year":"2017","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126563_bb0165","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2002-11-3569","article-title":"A role for toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells","volume":"101","author":"Bernasconi","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126563_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.12.063","article-title":"Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics","volume":"30","author":"Horns","year":"2020","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126563_bb0175","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1189\/jlb.0407214","article-title":"Polyclonal B cell activation in infections: infectious agents\u2019 devilry or defense mechanism of the host?","volume":"82","author":"Montes","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126563_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126563_bb0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.immuni.2007.04.007","article-title":"Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1","volume":"26","author":"Kallies","year":"2007","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126563_bb0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1074-7613(03)00267-X","article-title":"Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells","volume":"19","author":"Shapiro-Shelef","year":"2003","journal-title":"Immunity"},{"issue":"25","key":"10.1016\/j.vaccine.2024.126563_bb0195","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2009-07-235960","article-title":"An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization","volume":"114","author":"Jourdan","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126563_bb0200","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nri2204","article-title":"BLIMP1 guides the fate of effector B and T cells","volume":"7","author":"Nutt","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126563_bb0205","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.it.2023.10.008","article-title":"Leveraging human immune organoids for rational vaccine design","volume":"44","author":"Kastenschmidt","year":"2023","journal-title":"Trends Immunol"},{"issue":"41","key":"10.1016\/j.vaccine.2024.126563_bb0210","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1016\/j.vaccine.2017.03.099","article-title":"The in vitro MIMIC\u00ae platform reflects age-associated changes in immunological responses after influenza vaccination","volume":"35","author":"Dauner","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126563_bb0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03173.x","article-title":"Toll-like receptors--sentries in the B-cell response","volume":"128","author":"Bekeredjian-Ding","year":"2009","journal-title":"Immunology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T14:48:07Z","timestamp":1735656487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24012453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":43,"alternative-id":["S0264410X24012453"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126563","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126563"}}